Together Against Bacterial Infections


Vienna - Intercell AG has signed a license agreement with the pharmaceutical company Merck & Co., Inc. for the development of certain bacterial vaccines and an option to develop antibody products. As a result of this extended agreement, Intercell will receive upfront-, license-, and milestone-payments for a vaccine product. If Merck exercises the option for an antibody product, the Vienna-based company will obtain additional payments and royalty payments on product sales. Merck receives exclusive worldwide rights to commercialize any products that may be developed under the agreement. Further financial details were not disclosed.
This license agreement is the continuation of a research collaboration with Merck that began three years ago. During this collaboration, Intercell applied its Antigen Identification Program (AIP) to identify relevant antigens directed towards a specific bacterial target.



Vienna – Apeiron Biologics has entered into an exclusive option with the Cleveland Clinic to license a number of novel compounds that are currently in development there. The drug candidates are designed to fight cancer by...



Vienna – Austrian vaccine specialist Intercell has halted the development of its travellers’ diarrhea vaccine patch after the product failed in a Phase III trial. The company’s management says it will now align its structure to...

Clinical Trial, AustriaAustria


Vienna – Austrian Nabriva Therapeutics AG has recruited 210 patients for a Phase II study with its antibiotic BC-3781, a substance for treating acute bacterial skin infections. In the study, Nabriva will compare response rates of...



Vienna/Darmstadt – Austrian Apeiron Biologics AG has in-licensed Merck's KgaA’s antibody-interleukin fusion protein hu14.18-IL2 for an undisclosed sum. The drug candidate, that is ready to be tested in Phase III studies, binds to...



Vienna – Austrian Affiris AG has bagged EUR368.000 from the Michael J. Fox Foundation within the Parkinson’s Progression Markers Initiative for completion of preclinical development of its PD01 vaccine against Parkinson’s...



Innsbruck – Cholesterol-lowering drugs widely used to prevent heart disease can also boost anti-cancer effect of interleukine-2 (IL-2) immune therapy. When added to tumour cell cultures treated with IL-2, statins dose-dependently...

Displaying results 11 to 20 out of 116

< Previous 11-20 Next >

© 2007-2014 BIOCOM

Product of the week



All Events

Current issue

All issues